Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-RACER20 real-world study of amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC
jRCT1071250104Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amivantamab, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Primary endpoint: 1-year progression-free survival rate. Started Dec 2025; status: recruiting.
02
Drugs
amivantamabcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1071250104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250104.